Rocio Dominguez-Vidaña

Rocio Dominguez-Vidaña

Auto-generated profile, based on publicly available information

Rocio Dominguez-Vidaña

Baylor College of Medicine, Houston, TX

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2015 in Nature
Verified
Journal Article
Open access
PDF file
THTiffany Y.-T. Hsu
Tiffany Y.-T. Hsu
LSLukas Mikolaj Simon
Lukas Mikolaj Simon
NNNicholas J. Neill
Nicholas J. Neill
RMRichard Marcotte
Richard Marcotte
ASAzin Sayad
Azin Sayad
TWThomas F. Westbrook
Thomas F. Westbrook
Splicing factors such as BUD31 are identified in a synthetic-lethal screen with cells overexpressing the transcription factor MYC; oncogenic MYC leads to an increase in pre-mRNA synthesis, and spliceosome inhibition impairs the growth and tumorigenicity of MYC-dependent breast cancers, suggesting that spliceosome components may be potential therapeutic targets for MYC-driven cancers. The transcription factor MYC is frequently amplified or overexpressed in cancer and drives increased RNA and protein production. Here, Thomas Westbrook and colleagues identify the splicing factor BUD31 in a synthetic lethal screen with cells overexpressing MYC and show that other splicing factors are also required for cells to tolerate overexpressed MYC. Oncogenic MYC leads to an increase in pre-mRNA synthesis, and inhibition of the spliceosome impairs the growth and tumorigenicity of MYC-dependent breast cancer cells. Spliceosome components may therefore be potential therapeutic targets for MYC-driven cancers. MYC (also known as c-MYC) overexpression or hyperactivation is one of the most common drivers of human cancer. Despite intensive study, the MYC oncogene remains recalcitrant to therapeutic inhibition. MYC is a transcription factor, and many of its pro-tumorigenic functions have been attributed to its ability to regulate gene expression programs1,2,3. Notably, oncogenic MYC activation has also been shown to increase total RNA and protein production in many tissue and disease contexts4,5,6,7. While such increases in RNA and protein production may endow cancer cells with pro-tumour hallmarks, this increase in synthesis may also generate new or heightened burden on MYC-driven cancer cells to process these macromolecules properly8. Here we discover that the spliceosome is a new target of oncogenic stress in MYC-driven cancers. We identify BUD31 as a MYC-synthetic lethal gene in human mammary epithelial cells, and demonstrate that BUD31 is a component of the core spliceosome required for its assembly and catalytic activity. Core spliceosomal factors (such as SF3B1 and U2AF1) associated with BUD31 are also required to tolerate oncogenic MYC. Notably, MYC hyperactivation induces an increase in total precursor messenger RNA synthesis, suggesting an increased burden on the core spliceosome to process pre-mRNA. In contrast to normal cells, partial inhibition of the spliceosome in MYC-hyperactivated cells leads to global intron retention, widespread defects in pre-mRNA maturation, and deregulation of many essential cell processes. Notably, genetic or pharmacological inhibition of the spliceosome in vivo impairs survival, tumorigenicity and metastatic proclivity of MYC-dependent breast cancers. Collectively, these data suggest that oncogenic MYC confers a collateral stress on splicing, and that components of the spliceosome may be therapeutic entry points for aggressive MYC-driven cancers.

20 January 2012 in Science
Verified
Journal Article
Closed access
PDF file
JKJessica D. Kessler
Jessica D. Kessler
KKKristopher T. Kahle
Kristopher T. Kahle
TSTingting Sun
Tingting Sun
KMKristen L. Meerbrey
Kristen L. Meerbrey
MSMichael R. Schlabach
Michael R. Schlabach
TWThomas F. Westbrook
Thomas F. Westbrook
Taking the Myc: Despite nearly 30 years of research into the mechanisms by which Myc oncogene dysregulation contributes to tumorigenesis, there are still no effective therapies that inhibit Myc activity. Kessler et al. (p. 348 , published online 8 December; see the Perspective by Evan ) searched for gene products that support Myc-driven tumorigenesis. One pharmacologically tractable target that emerged from the screen was the SUMO-activating enzyme complex SAE1/2, which catalyzes a posttranslational modification (SUMOylation) that alters protein behavior and function. SUMOylation was found to control the Myc transcriptional response, and its inhibition caused mitotic defects and apoptosis in Myc-dependent breast cancer cells.

10 April 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MFMargarita Flores
Margarita Flores
LMLucía Morales
Lucía Morales
CGClaudia Gonzaga-Jauregui
Claudia Gonzaga-Jauregui
RDRocío Domínguez-Vidaña
Rocío Domínguez-Vidaña
CZCinthya Zepeda
Cinthya Zepeda
RPRafael Palacios
Rafael Palacios
Several lines of evidence suggest that reiterated sequences in the human genome are targets for nonallelic homologous recombination (NAHR), which facilitates genomic rearrangements. We have used a PCR-based approach to identify breakpoint regions of rearranged structures in the human genome. In particular, we have identified intrachromosomal identical repeats that are located in reverse orientation, which may lead to chromosomal inversions. A bioinformatic workflow pathway to select appropriate regions for analysis was developed. Three such regions overlapping with known human genes, located on chromosomes 3, 15, and 19, were analyzed. The relative proportion of wild-type to rearranged structures was determined in DNA samples from blood obtained from different, unrelated individuals. The results obtained indicate that recurrent genomic rearrangements occur at relatively high frequency in somatic cells. Interestingly, the rearrangements studied were significantly more abundant in adults than in newborn individuals, suggesting that such DNA rearrangements might start to appear during embryogenesis or fetal life and continue to accumulate after birth. The relevance of our results in regard to human genomic variation is discussed.

26 March 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ANAmritha Nair
Amritha Nair
HCHsiang-Ching Chung
Hsiang-Ching Chung
TSTingting Sun
Tingting Sun
STSiddhartha Tyagi
Siddhartha Tyagi
LDLacey E Dobrolecki
Lacey E Dobrolecki
TWThomas F Westbrook
Thomas F Westbrook

1 November 2014 in Cell Reports
Verified
Journal Article
Open access
KKKristen L. Karlin
Kristen L. Karlin
GMGourish Mondal
Gourish Mondal
JHJessica K. Hartman
Jessica K. Hartman
STSiddhartha Tyagi
Siddhartha Tyagi
SKSarah J. Kurley
Sarah J. Kurley
TWThomas F. Westbrook
Thomas F. Westbrook
Defining the molecular networks that drive breast cancer has led to therapeutic interventions and improved patient survival. However, the aggressive triple-negative breast cancer subtype (TNBC) remains recalcitrant to targeted therapies because its molecular etiology is poorly defined. In this study, we used a forward genetic screen to discover an oncogenic network driving human TNBC. SCYL1, TEX14, and PLK1 ("STP axis") cooperatively trigger degradation of the REST tumor suppressor protein, a frequent event in human TNBC. The STP axis induces REST degradation by phosphorylating a conserved REST phospho-degron and bridging REST interaction with the ubiquitin-ligase βTRCP. Inhibition of the STP axis leads to increased REST protein levels and impairs TNBC transformation, tumor progression, and metastasis. Expression of the STP axis correlates with low REST protein levels in human TNBCs and poor clinical outcome for TNBC patients. Our findings demonstrate that the STP-REST axis is a molecular driver of human TNBC.

3 September 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JMJitendra K. Meena
Jitendra K. Meena
JWJarey H. Wang
Jarey H. Wang
NNNicholas J. Neill
Nicholas J. Neill
DKDianne Keough
Dianne Keough
Nagireddy PutluriNagireddy Putluri
Nagireddy Putluri
TWThomas F. Westbrook
Thomas F. Westbrook
Upregulation of MYC is a hallmark of cancer, wherein MYC drives oncogenic gene expression and elevates total RNA synthesis across cancer cell transcriptomes. Although this transcriptional anabolism fuels cancer growth and survival, the consequences and metabolic stresses induced by excess cellular RNA are poorly understood. Herein, we discover that RNA degradation and downstream ribonucleotide catabolism is a novel mechanism of MYC-induced cancer cell death. Combining genetics and metabolomics, we find that MYC increases RNA decay through the cytoplasmic exosome, resulting in the accumulation of cytotoxic RNA catabolites and reactive oxygen species. Notably, tumor-derived exosome mutations abrogate MYC-induced cell death, suggesting excess RNA decay may be toxic to human cancers. In agreement, purine salvage acts as a compensatory pathway that mitigates MYC-induced ribonucleotide catabolism, and inhibitors of purine salvage impair MYC+ tumor progression. Together, these data suggest that MYC-induced RNA decay is an oncogenic stress that can be exploited therapeutically. Significance: MYC is the most common oncogenic driver of poor-prognosis cancers but has been recalcitrant to therapeutic inhibition. We discovered a new vulnerability in MYC+ cancer where MYC induces cell death through excess RNA decay. Therapeutics that exacerbate downstream ribonucleotide catabolism provide a therapeutically tractable approach to TNBC (Triple-negative Breast Cancer) and other MYC-driven cancers.